Pasar al contenido principal

IMPLICACION DE LA REACTIVIDAD GLIAL EN EPILEPTOGENESIS MEDIANTE ESTUDIOS LONGITUDINALES DE NEUROIMAGEN PET-MRI

PID2019-106968RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

[18F]FDG-PET as a tool to discover the role of astrocytes in brain metabolism

  • Hernández Martín, Nira
  • Bascuñana, Pablo
  • Fernandez de la Rosa, Ruben
  • Garcia Garcia, Luis
  • Solas, M. Teresa
  • Martín, Eduardo D.
  • Pozo, Miguel A. del
Introduction Astrocytes are a group of brain cells that plays a crucial role in brain metabolism. Even though these cells are well characterized, its mechanisms in brain glucose regulation remains unknown. Chemogenetics is a revolutionary technique, as it allows modulating different populations of cells through Drug Receptors Exclusively Activated by Designer Drugs (DREADDs). Our study aims to activate hippocampal astrocytes with DREADDs in different mutant animal models and evaluate changes in brain glucose kinetic. Methods Our study aimed to use chemogenetic to activate hippocampal astrocytes in wild type mice and in two animal models of knock out in astrocytes: Inositol 3 Phosphate KO (IP3-/-) and Glucose Transporter 1 KO (GLUT1-/-). Positron Emission Tomography (PET) combined with the glucose analog radiotracer 2-deoxy-2- [18F]-fluoro-D-glucose (FDG) imaging technique was used in dynamic studies to evaluate changes in glucose kinetics based on a 2-tissue-compartment model (2TC). FDG was injected 10 minutes after the activation drug, Clozapine-N-Oxide (CNO 3 mg/kg i.p.), or saline. Both conditions were performed in the same animals. Results/Discussion Our results in WT mice revealed that activation of astrocytes by CNO increased the uptake of FDG. Analysis through kinetic model showed that DREADDs activation with CNO increased glucose influx. Astrocyte activation in IP3-/- mice (animals with an impairment of calcium signaling) had no effect in FDG PET studies. Baseline GLUT1-/- mice showed higher levels of FDG uptake compared to WT animals in the kinetic model. When DREADDs were activated in GLUT1-/- mice there was no effect in 2TC model, suggesting that this glucose transporter is responsible of the increase in FDG uptake due to chemogenetics in astrocytes. Conclusions Activation of DREADDs with CNO induces an increase of glucose consumption in mouse brain. This effect is not observed in GLUT1-/- and IP3-/- mice. Thus, CNO is specifically activating astrocytes and the null effect on mutant mice suggests that DREADDs activation is inducing calcium signaling and, therefore, increasing glucose uptake through GLUT1. The results obtained in this study propose that changes in metabolism mostly depends on astrocytes., This work was funded by Spanish Agencia Estatal de Investigación (MICINN Spain PDI2019-106968RB-100). Presenting author received the Alfonso Casanavas scholarship of Universidad Complutense de Madrid.